Scientists around the word are debating the scientific and ethical possibilities of using powerful gene editing tools, such as the CRISPR/Cas9 system, to treat heritable diseases in human embryos. In 1987, the discovery of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) genes in single celled prokaryotic systems revolutionized genetic engineering. Initially thought to be